

# Carbon Reduction Plan Template

Supplier name: medac Pharma LLP

Publication date: 12/07/2024

## Commitment to achieving Net Zero

medac Pharma LLP is committed to achieving Net Zero emissions by 2045.

In January 2024, the leadership team of medac Pharma LLP committed to reducing carbon emissions by 30% by 2045, as well as achieving net zero by 2045.

## Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

### Baseline Year: 2022-23 (Financial Year)

#### Additional Details relating to the Baseline Emissions calculations.

medac Pharma LLP do not manufacture any of the products sold to the NHS in the UK, nor do they own or control any vehicles or ships that transport products to the UK. Therefore, medac Pharma LLP do not have any Scope 1 emissions. Transportation of products to the UK is outsourced by medac GmbH to Schmechel Transport GmbH. The emissions relating to transportation to the UK by Schmechel Transport GmbH are included as upstream transportation emissions in Scope 3.

medac Pharma LLP do not own or control any vehicles for distribution of products within the UK. This is outsourced to Alliance Healthcare UK (AHUK) and Alloga UK, and the distribution emissions relating to Alliance and Alloga that are attributed to medac products are included in Scope 3 as downstream distribution emissions.

### Baseline year emissions: 2022 – 23 (financial year)

EMISSIONS	TOTAL (tCO <sub>2</sub> e)
Scope 1	0
Scope 2	6.1

<b>Scope 3</b> (Included Sources)	Upstream Transportation (Schmechel)	19.2
	Waste Disposal	1.0
	Shred-it Paper Emissions	~0.0
	Business Travel	74.9
	Employee Commuting	29.2
	Downstream Distribution (Alloga & Alliance)	98.1
	<b>Total Scope 3 Emissions</b>	<b>222.4</b>
<b>Total Emissions</b>	228.5	

## Current Emissions Reporting


<b>Reporting Year: 2023 – 24 (Financial year)</b>		
<b>EMISSIONS</b>	<b>TOTAL (tCO<sub>2</sub>e)</b>	
<b>Scope 1</b>	0	
<b>Scope 2</b>	5.9	
<b>Scope 3</b> (Included Sources)	Upstream Transportation (Schmechel)	24.3
	Waste Disposal	1.0
	Shred-it Paper Emissions	~0.0
	Business Travel	74.9
	Employee Commuting	29.2
	Downstream Distribution (Alloga & Alliance)	97.0
	<b>Total Scope 3 Emissions</b>	<b>226.4</b>
<b>Total Emissions</b>	232.3	

## Emissions reduction targets

In order to continue our progress to achieving Net Zero, we have adopted the following carbon reduction targets.

We project that carbon emissions will decrease over the next five years to 211 tCO<sub>2</sub>e by 2029, assuming similar volume of transactional activities conducted by medac Pharma LLP. This is a reduction of 9.2% from FY 2023-24.

Progress against these targets can be seen in the graph below:



## Carbon Reduction Projects

### Completed Carbon Reduction Initiatives

medac Pharma LLP is committed to achieving Net Zero and Carbon offsetting targets. As a company, we have already put into action the following:

- Switch to a 70% renewable energy supplier for the office
- Introduction of DocuSign to reduce printing and save paper
- Hybrid working, home working and virtual meetings: lessening commuting and business travel
- Engage with the supply chain both domestic and international to ensure commitment to environmental plans and projects – net Zero by 2045
- Segregating and recycling of all office waste

medac Pharma GmbH, the parent company of medac Pharma LLP, have received ISO 14001 certification.

In the future we hope to implement further measures such as:

- Low carbon energy consumption – find supplier of 100% renewable energy consumption
- Employee engagement and education
- Supply chain engagement and education
- Energy efficiency in our buildings
- Employee mobility and travel

## Declaration and Sign Off


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard<sup>1</sup> and uses the appropriate Government emission conversion factors for greenhouse gas company reporting<sup>2</sup>.

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard<sup>3</sup>.

This Carbon Reduction Plan has been reviewed and signed off by the General Manager of medac Pharma LLP.

### Signed on behalf of the Supplier:



A handwritten signature in black ink, appearing to read 'Hannah Teather', is written over a horizontal dotted line.

Signed on behalf of medac Pharma LLP by Hannah Teather, General Manager  
Date: 11/7/24.....

---

<sup>1</sup><https://ghgprotocol.org/corporate-standard>

<sup>2</sup><https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

<sup>3</sup><https://ghgprotocol.org/standards/scope-3-standard>